PAMA Manufacturing and Sterilization has partnered with HP Canada and its consortium of 11 small businesses across Canada that specialize in 3D printing and digital manufacturing, to support national requirements for Personal Protective Equipment (PPE) and COVID-19 test.
3DP swabs have passed the clinical trials sanctioned by Health Canada. In the meantime, HP and its partners, including PAMA, have worked with other countries outside of Canada, such as the United States, Belgium, France, Norway and Spain as well as well-known organizations as the US military, to deliver millions of 3DP swabs.
These swabs have undergone regulatory approval with Health Canada (IO # 314006).
PAMA Manufacturing and Sterilization aims to support our country’s COVID-19 testing requirements by producing up to 100 million nasopharyngeal swabs through the use of HP 3D Printing Technology (3DP). Swabs can be packaged individually or as part of a kit with transport media (PBS or VTM).
PAMA will lead its own swab supply chain and be responsible for the final efforts: